Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1424-1430

  Paydas, Semra ^a   Ergin, Melek ^a   Erdogan, Seyda ^a   Seydaoglu, Gulsah ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; EBV; NHL; Prognosis; VEGF A; Viral lymphangiogenesis

Indexed keywords

LATENT MEMBRANE PROTEIN 1; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL MATRIX PROTEINS;

EID: 43049153419     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.008     Document Type: Article

References (36)

1. Timms J.M., Flavell J.R., Murray P.G., Rickinson A.B., Traverse-Glehen A., Berger F., et al. Target cells of Epstein-Barr-virus (EBV)-positive posttransplant lymphoproliferative disease: similarities to EBV-positive-Hodgkin's lymphoma. Lancet 361 (2003) 217-223
2. Siu L.L., Chan J.K., and Kwang Y.L. Natural killer cell malignancies: clinicopathological and molecular features. Histol Histopathol 17 (2002) 539-554
3. Horenstein M.G., Nador R.G., Chadburn A., Hyjek E.M., Inghirami G., Knowles D.M., et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpes virus/human herpesvirus-8. Blood 90 (1997) 1186-1191
4. Fukayama M., Ibuka T., Hayashi Y., Oaba T., Koike M., and Mizutani S. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol 143 (1993) 1044-1049
5. Weiss L.M., Chen Y., Liu X.F., and Shibata D. Epstein-Barr virus and Hodgkin's disease: correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 139 (1991) 1259-1265
6. Weinreb M., Day P.J., Niggli F., Powell J.E., Raafat F., Hesseling P.B., et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child 74 (1996) 27-31
7. Al-Kuraya K., Narayanappa R., Al-Dayed F., El-Solh H., Ezzat A., Ismail H., et al. Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leuk Lymphoma 47 (2006) 707-713
8. Middldorp J.M., Brink A.A.T.P., van den Brule A.J.C., and Meijer C.J.L.M. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45 (2003) 1-36
9. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., and Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 91 (2000) 1233-1240
10. Park S., Lee, Ko Y.H., Han A., Jun C.W., Lee C.S., et al. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood 110 (2007) 972-978
11. Claviez A., Tiemann M., Luders H., Krames M., Parvaresch R., Schellony G., et al. Impact of latent Epstein-Barr virus infection on outcome in adolescents with Hodgkin's lymphoma. J Clin Oncol 23 (2006) 4048-4056
12. Jarret R.F., Stark G.L., White J., Angus B., Alexander F.E., Krajevski A.S., et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 108 (2005) 2444-2451
13. Herling M., Rassidakis G.Z., Medeiros L.J., Vassilakopoulos T.P., Kliche K.O., Nadali G., et al. Expression of Epstein Barr virus latent membrane protein 1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma associations with presenting features, serum levels of IL-10 and clinical outcome. Clin Cancer Res 9 (2003) 2114-2120
14. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
15. Wakisaka N., Kondo S., Yoshizaki T., Murono S., Furukawa M., and Pagano J.S. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia inducible factor 1 alpha. Mol Cell Biol 24 (2004) 5223-5234
16. Hong G.K., Kumar P., Wang L., Damania B., Gulley M.L., Delecluse H.J., et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Viol 79 (2005) 13984-13992
17. Quian C.N., Min H.Q., Lin H.L., Hong M.H., and Ye Y.L. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 112 (1998) 849-853
18. Yoshizaki T., Horikawa T., Quing-Chun R., Wakisaka H., Takeshita H., Sheen T.S., et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 7 (2001) 1946-1951
19. Yao L., Setsuda P.J., Parekh J., Gupta G., Jaffe R.E.S., and Tosato G. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96 (2000) 1900-1905
20. Glaser S.L., Gulley M.L., Borowitz M.J., Craig F.E., Mann R.B., Stewart S.L., et al. Inter and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma 45 (2004) 489-547
21. Known J.M., Park Y.H., Kang J.H., Kim K., Ko Y.H., Ryoo B.Y., et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 85 (2006) 463-468
22. d'Amore F., Johansen P., Houmand A., Weisenburger D.D., and Mortensen L.S. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 87 (1996) 1045-1055
23. Tsimberidou A.M., Keating M.J., Bueso-Ramos C.E., and Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47 (2006) 827-836
24. Salven P., Teerenhovi L., and Joensun H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
25. Kini A.R., Day N.E., and Peterson L.C. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 14 (2000) 1414-1418
26. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 28 (2004) 595-604
27. Ho C.L., Sheu L.F., and Li C.Y. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 10 (2002) 316-321
28. Moehler T.M., Ho A.D., Goldschmidt H., and Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 45 (2003) 227-244
29. Jorgensen J.M., Sorensen F.B., Bendix K., Nielsen J.L., Olsen M.L., Funder A.M.D., et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48 (2007) 584-595
30. Korkolopoulou P., Thymara I., Kavantzas N., Vassilakopoulos T.P., Kokoris S.I., Dmitriadou E.M., et al. Angiogenesis in Hodgin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 1 (2005) 894-900
31. Hazar B., Paydas S., Zorludemir S., Sahin B., and Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 44 (2003) 2089-2093
32. Gratzinger D., Zhao S., Marinelli R.J., Kapp A.V., Tibshirani R.J., Hammer A.S., et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B cell lymphoma subtypes. Am J Pathol 170 (2007) 1362-1369
33. Murano S., Inoue H., Tanabe T., Joab I., Yoshizaki T., Furukawa M., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved vascular endothelial growth factor production in nasopharyngeal carcinoma cells. PNAS 98 (2001) 6905-6910
34. Krishna S.M., James S., and Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115 (2006) 85-90
35. Keegan T.H.M., Glaser S.L., Clarke C.A., Gulley M.L., Craig F.E., DiGiuseppo J.A., et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 23 (2005) 7604-7613
36. Levine A.M., Tulpule A., Quinn D.I., Gorospe G., Smith L., Hornor L., et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 24 (2006) 1712-1719